Item 2.02 Results of Operations and Financial Condition.
On May 12, 2022, LianBio (the “Company”) issued a press release announcing its
financial results for the fiscal quarter ended March 31, 2022. A copy of the
press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On May 12, 2022, the Company posted an updated corporate presentation to its
website. A copy of the corporate presentation is furnished as Exhibit 99.2 to
this Current Report on Form 8-K. The Company undertakes no obligation to update,
supplement or amend the materials attached hereto as Exhibit 99.2.
The information contained in this Current Report on Form 8-K, including Exhibit
99.1 and Exhibit 99.2 attached hereto, is being furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits Exhibit No. Description 99.1 Press release issued by LianBio, dated May 12, 2022 99.2 LianBio corporate presentation as of May 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses